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LGMD2B  is  a  frequent  proximo-distal  myopathy  with  rapid 
evolution after age 20. Exacerbating factors may be physical ex-
ercise and inflammation. There is very little information about 
the effect of sportive activity in LGMD2B, since eccentric exer-
cise frequently results in muscle damage. LGMD2B has often an 
onset with myalgia and MRI imaging (STIR-sequences) shows 
myoedema. In a prolonged observational study of a series of 18 
MM/LGMD2B patients we have studied the pattern of clinical 
and radiological evolution. The disease has an abrupt onset in the 
second decade and most patients perform sports before definite 
disease onset. On the basis of Gardner-Medwin and Walton scale, 
grade 4 is reached two years faster in patients who performed 
sports (over 1000 hours). Other considerations regarding patho-
genetic mechanism and response to treatment show a poor re-
sponse to immunosuppressive treatment of muscle inflammation. 
Preventing a strenuous physical activity should be recommended 
in patients with high CK and diagnosed or suspected to have dys-
ferlin deficiency. 
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Introduction
Dysferlinopathy represents a peculiar limb-girdle mus-
cular  dystrophy,  with  a  particular  challenge  for  the  par-
tially unsolved pathogenesis. The recognition of the two 
main phenotypes of distal Miyoshi Myopathy (MM) and 
proximal LGMD2B (1-5) were done early; most descrip-
tions dealt with inbred populations or families with a lim-
ited number of mutations. Subsequent studies have reported 
larger numbers of patients with sporadic mutations and ex-
tended the clinical spectrum, to include onset in early child-
hood or adult age. In a large group of patients, in whom 
a clear distinction in their pattern of muscle involvement 
into Miyoshi or LGMD was not possible, an involvement 
of both the proximal and distal musculature was observed 
in most patients, especially as the disease progresses (6-8). 
The frequency of dysferlinopathy provides a further chal-
lenge. Dysferlinopathy appears to be a relatively common 
cause of LGMD in Southern European populations. Founder 
mutations exist in only a few small communities (6, 9, 10). 
Dysferlinopathy can be diagnosed mainly by Western blot-
ting and, in fact, although the clinical diagnostic process by 
which dysferlinopathy is diagnosed is variable, most labo-
ratories still rely on the diagnosis by muscle immunoblot-
ting as the most reliable method, versus immunohistochem-
istry (11-13). Some laboratories carry out protein testing on 
monocytes as an alternative screening methodology (14). 
The gold standard for dysferlinopathy diagnosis is however 
DNA testing, with sequencing carried out in a small number 
of laboratories in Europe and the USA (7, 17).
A limitation of all LGMD2B studies however is that, 
with few exceptions, long-term follow-up data are not 
presented and data on clinical progression are collected 
in different ways, making precise comparisons between 
their conclusions difficult. Klinge et al. (5, 8) have ob-
served that a unique finding within the spectrum of mus-
cular  dystrophies  is  that  the  majority  of  patients  with 
dysferlin deficiency appear to have good muscle strength 
before onset of symptoms, leading to good performance 
at sports or to the ability to cope well with physically de-
manding activities; 53% of the patients were very active 
in sports before onset of clinical symptoms,which makes 
the clinical course of dysferlinopathy unusual and pro-
vides a challenge to understanding the underlying patho-
genesis in this disease.
Material and methods
Natural history
Recently, two studies have addressed more systemati-
cally the topic of the natural history of dysferlinopathy. A 
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study of 9 genetically confirmed LGMD2B and MM patients 
studied over 18 months, demonstrated a significant decline in 
muscle strength in a set of muscle groups measured by man-
ual muscle testing, and in knee flexion measured by quantita-
tive muscle testing, accompanied by a detectable deteriora-
tion on MRI in biceps femoris and tibialis posterior (15).
It is likely that in dysferlinopathy there are changes 
detectable with time that could address the design of fu-
ture clinical trials, but the optimal measurements have yet 
to be defined representing the entire clinical spectrum of 
this diverse disease group.
Aims of the study
The primary aims of this study are the following:
a.  To describe a cohort of patients with dysferlinopathy 
in terms of clinical, functional, strength and quality 
of life assessments, as well as for MRI results, and to 
explore associations between these assessments and 
gender, age, clinical distribution of muscle involve-
ment/mode  of  presentation,  physical  activity  (in 
sports) versus non active prior to onset (cut-off 1000 
hours) relationship of onset and deterioration.
b.  To describe changes over time in these parameters over 
a eight year period and define the outcome measures 
capable of capturing this information most reliably.
Additional aims are:
1.  To define the natural history of dysferlinopathy in an 
unselected patient group with respect to age and type 
of onset, and progression.
2.  To study a selection of possible outcome measures 
for dysferlinopathy trials over a eight year period of 
18 patients followed in our centre of excellence for 
muscular dystrophy diagnosis and management.
Patient questionnaire
As part of the natural course study, we collected di-
rectly from the patients the information about their dis-
ease onset and progression. This part of the study was 
done  using  a  questionnaire  by  direct  interview  during 
the hospitalization or outpatient examinations and basic 
natural history data were obtained on a group of patients. 
Briefly,  patients  were  informed  about  the  more  inten-
sive clinically based protocol during an examination and 
given details to obtain genetic information, as well as of 
diagnosis. There was a cross-linking between the patient 
reported information and the clinician and physiothera-
pist- reported data collected at clinical reviews.
Clinical study of outcome measures and MRI
The data reported by the patients do not provide suf-
ficient detail to exactly determine the performance of spe-
cific outcome measures in this group. For this purpose, 
our group of clinical evaluators worked on a set of evalua-
tions (GSGCA scale) over a eight year time period, evalu-
ating a group of 18 patients with proved dysferlinopathy 
by western blotting and mutation analysis (16, 17), repre-
senting the full spectrum of disease.
The  diagnostic  and  neuromuscular  protocol  define 
inclusion and exclusion criteria for entry into the study 
(Table 1), collects baseline and follow-up data on inves-
tigations, including muscle biopsy, onset and its relation 
to sporting prowess, number of hours performed in vari-
ous sporting activities, gender, clinical status, associated 
symptoms and levels of disability. Cardiac involvement 
was assessed by echocardiography and electrocardiog-
raphy at the beginning and during the follow-up of the 
study.
table 1.
A. Inclusion criteria
Confirmed diagnosis of dysferlinopathy proven by a) two mutant alleles in the dysferlin gene (either homozygous 
mutation or compound heterozygous mutations) or b) one mutant allele and absent/severely reduced dysferlin 
amount on muscle immunoblot. Mutations were checked for their pathogenicity (16, 17).
Ambulant patients with or without aids were included; if a full-time wheelchair user only a certain number (1/4 of 
total number) of tests were done.
Ability to perform assessments (there are different assessments for ambulant and non-ambulant patients).
Informed consent to participate in the study.
Known current or planned medical or other interventions that might interfere with the possibility to undertake the 
planned tests.
Other concomitant pathology that in the view of the investigator would jeopardise the ability to take part in the 
protocol.
B. Exclusion criteria
Non ambulant patients
Patients who could not come for clinical examinationSport activity in dysferlinopathy
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The  physical  exams  documented  muscle  strength, 
motor function and pulmonary function in ambulant and 
non-ambulant patients with the generally slowly progres-
sive muscle weakness, taking into account the variable 
presentation in this condition. Clinical examination was 
done every year or less.
Protocol
At each bi-annual examination we performed:
•	 General	clinical	questionnaire	to	include	also	sport-
ing activity
•		 Update	on	motor	functions	and	other	medical	ques-
tions
•		 Update	on	current	medication
•		 General	physical	examination
•		 Cardiological	exams
•		 Respiratory	exams
•		 General	neurological	exam	including	muscle	assess-
ment
•		 GSGCA	assessment
1.  Manual Muscle Testing (MRC scale) on the follow-
ing muscle groups:
Hip flexors
Hip extensors
Hip abductors
Hip adductors
Knee flexors
Knee extensors
Ankle dorsiflexors
Ankle plantar flexors
Neck flexors
Neck extensors
Shoulder abductors
Shoulder flexors
Biceps brachii
Brachioradialis
Elbow extensors
Wrist extensors
Wrist flexors
Grip
Finger flexors
2.  Timed Tests:
G = 10 m walk
S = Timed climb 4 stairs
G = to raise from floor (Gowers)
C = Timed to raise from Chair
A = arms manoeuvre
GSGCA functional scale score ranges from 4 to 35 
grades.
3.  Modified Gardner-Medwin and Walton scale
The clinical course of both diseases has been evalu-
ated with 9 grades of the modified Gardner- Medwin-
Walton as previously described (18): grade 0 = hyperCK-
emia, all activities normal; grade 1 = normal gait, unable 
to run freely, myalgia; grade 2 = incapacity to walk on 
tiptoes, waddling gait; grade 3 = evident muscular weak-
ness, steppage and climbing stairs with banister; grade 
4 = difficulty to rise from the floor, Gowers’ sign; grade 
5 = incapacity to rise from the floor; grade 6 = incapacity 
to climb stairs; grade 7 = incapacity to rise, from a chair; 
grade 8 = unable to walk unassisted; grade 9 = unable to 
eat, drink or sit without assistance.
CT and MRI procedures
In  the  case  of  dysferlinopathies,  MRI  studies  have 
led to the observation that the muscles affected earlier are 
Gastrocnemius Medialis in the leg or Adductor Magnus in 
thigh. Furthermore, muscle involvement can be detected 
as a hyper-intensity on STIR sequences before it is clini-
cally evident (18, 19). The muscles affected later are Vastus 
Lateralis and Soleus, and in the final stages of the disease, 
muscle wasting is diffuse, with a relative preservation of 
the Biceps Femoris and the Deep Flexors of the leg.
This particular pattern can be used to distinguish dys-
ferlinopathies from other dystrophies and myopathies. A 
more precise analysis of the natural history of this dis-
ease will create a sound base on which to make a clinical 
prognosis.
The aim of this study was to better determine which 
muscles are involved in dysferlinopathies and to define 
the rate of progression of the disease. We evaluated the 
value of MRI as a surrogate marker of progression of the 
disease.
Muscle CT scan of the whole body was also used. We 
assessed the degree of impairment of each muscle and the 
extent of involvement of the different muscles in the disease 
and tried to establish the rate of progression (Fig. 1).
Statistical analysis
A population of 18 patients is large enough to accom-
plish our aim and to detect a difference of approximate-
ly 0.5 SD in any parameter of muscle strength between 
groups that have a ratio of 2:1 with 80% power while con-
trolling for a Type I error of 0.05. Correlations as modest 
as 0.30 can be detected with approximately 90% power.
results
The finding of sportive activity as an adverse event to 
dysferlinopathy course appears of interest: sport in effect 
is associated with eccentric muscle exercise and might C. Angelini et al.
130
deliver cytokines in muscle. This in turn might determine 
local  inflammation  and  myoedema  on  MRI  that  often 
contributes and exacerbate disease course.
We examined 18 patients (14 males and 4 females, 3 
pairs of brothers including 1 pairs of siblings). Two pa-
tients had consanguineous parents. The mean age was 33 
years, ranging from 16 to 50 years. At the time of this 
clinical-radiological study, 13 patients had MM pheno-
type, 3 patients had classical LGMD phenotype and 2 
patients had only hyperCKemia. The GSGCA functional 
scale showed the following data: 2 patients (12%) were 
asymptomatic with only hyperCKemia, 5 patients (28%) 
had difficulty in rising from the floor, 5 patients (28%) 
were unable to rise from the floor, 3 patients (17%) were 
unable in rising from a chair and 3 patients (17%) were 
not able to walk without assistance (18).
The further evolution of GSGCA score was variable 
in different patients. While the score increased rapidly in 
ambulant patients (Figs. 2, 3) it was much less progres-
sive in non-ambulant patients (Figs. 4, 5).
We evaluated 17 patients by MRI imaging (T1, T2, 
STIR sequences). There was an inverse linear correlation 
Figure 1. Derived evolution of several muscle compart-
ment in 14 LGMD2B/Miyoshi patients studied by CT scan. 
First distal posterior leg muscles show dystrophic chang-
es (A), then posterior thigh muscles (B), subsequently an-
terior leg muscle (C) and finally upper limb muscles (D).
Figure 2. Two-year difference in time to reach grade 4 in 
7 sportive versus 5 non-sportive LGMD2B patients. Cut-
off time was put at 1000 hours of different sports (swim-
ming, body building, soccer, cyclette, mountain bike, jog-
ging, karate, basket, volley, dancing, gym, ski, hip-hop 
dancing) or outside working physical activity. A worsen-
ing in motor function was seen in sportive patients before 
disease onset.
Figure 3. Time in years (mean = 8 years) to reach grade 
4 of GMW scale in 10 LGMD2B patients.
Figure 4. Evolution of GSGCA scale in a period of 8 
years (from 2001 to 2009) in 12 LGMD2B patients. There 
is  a  worsening  of  functional  grade  performances  that 
occurs at different times. The values of grades over 25 
already express a severe involvement and therefore a fur-
ther functional worsening is unlikely.
Figure 5. Last clinical examination in two affected broth-
ers: inability to lift arms (left-hand panel) and difficulty 
climbing stairs (right-hand panel).Sport activity in dysferlinopathy
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between Mercuri (T1) score and muscle strength (MRC 
scale): Pearson Index (r) = -0.84; p < 0.001. There was a 
direct linear correlation between Mercuri (T1) score and 
disability score (GSGCA disability scale): Pearson Index 
(r) = 0.95; p < 0.005.
The distribution of fibro-fatty replacement in lower 
limbs was, also, investigated: in 15 patients (88%) the 
posterior compartment of the thigh and of the leg was 
more involved than the anterior; the mean fibro-fatty re-
placement grade in the posterior compartment of thigh 
and leg (% respect to the entire posterior compartment 
of the thigh and leg) was 72.6% and 72.9%, respectively 
(Fig. 6). STIR sequences analysis reveals a hyper-intense 
signal (myoedema), also in these patients. The quanti-
fication of this inflammatory aspect (Myoedema score) 
reveals  a  particular  distribution:  in  14  patients  (82%) 
the anterior compartment of the thigh and leg is more in-
volved than the posterior. The mean myoedema grade in 
the anterior compartment of thigh and leg (% respect to 
the entire anterior compartment of thigh and leg) is, re-
spectively, 29.6% and 41.8% (Fig. 6).
Disease progression and clinical phenotype was also 
previously described (20).
No patients had cardiac involvement, but in few cases 
there was a moderate respiratory insufficiency.
In  all  cases  CK  levels  were  highly  elevated  (over 
1000 U/L).
Discussion
The definition of a particularly good level of sporting 
prowess before the onset of symptoms and the descrip-
tion of a subacute onset with muscle pain and swelling, 
if better understood, could potentially help in our under-
standing of the pathogenesis of the disease. In a group of 
unselected patients we have tested the hypothesis whether 
such sportive activity might influence disease course and 
progression.
Direct clinical comparison with different forms of 
muscular dystrophy is difficult, since there is no direct 
match in age of onset and progression. However, when 
we compared clinical progression of LGMD2B with LG-
MD2A, the majority of LGMD2A (20) did not perform 
sportive activities, they are not so good at sports or avoid-
ed sports at all before disease onset, and LGMD2A seems 
to have an indolent atrophic course.
Immunosuppressive  treatment  has  been  variably 
tried  in  LGMD  and  also  in  dysferlinopathy  patients. 
While other types of LGMD (LGMD2D, or LGMD2I) 
have  variably  responded  to  steroids,  most  reports  on 
dysferlin deficiency on steroids are negative and dysfer-
lin deficiency behaves as a refractory disease. In cases 
of uncertain diagnosis both immunohistological features 
and western blotting might help for an accurate diagno-
sis (17, 21, 22).
Also  in  view  of  inflammatory  cell  in  the  muscle, 
the administration of rituximab has been tried: two pa-
tients (23) had some improvement in muscle strength, 
especially in the isometric hand-grip contraction. To our 
knowledge, these are the only two cases with increased 
muscle grip but the report is anedoctical and an open-
trial. Furthermore, one of the two patients did not report 
any sustained benefit.
IVIg has also been tried with variable efficacy. In 
our experience, there might be some amelioration due 
to possible down-regulation of the complement inhibi-
tory factor CD55 but a real controlled trial has not yet 
been done.
Walker and a group of centers in Germany (data 
presented in Muscular Dystrophy Research Symposi-
um, 2010, Padova) assessed the natural course of dis-
ease and efficacy of deflazacort treatment in 25 patients 
(between 25 and 63 years of age) with genetically con-
firmed  dysferlinopathy  in  a  double-blind,  cross-over 
trial. During the first year of the study, they assessed 
the  natural  course  of  disease  in  6-month  intervals, 
evaluating MRC scores, quantitative strength measure-
ment by hand-held dynamometry, and torque measure-
ment, Neuromuscular Symptoms Score, Timed Func-
tion Tests (getting up from lying and sitting position, 
climbing 4 stairs, running 10m), Vignos Scale, Ham-
mersmith Motor Ability Score, and Global Assessment 
CGI Scale, quality of life SF-36 scale and laboratory 
parameters (sodium, potassium, creatinine, urea, GOT, 
GPT, gamma-GT, CK, blood count, ESR, CRP). Medi-
cation (placebo or deflazacort in a cross-over design) 
was only started in the second year of the study. All 
patients showed a decline in muscle strength over one 
year, which was reflected in the tests performed.
Figure 6. Fibro-fatty replacement (left-hand panel, T1 
sequence) and myoedema (right-hand panel, STIR se-
quence) on muscle MRI.C. Angelini et al.
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All studies agree that dysferlinopathy is a chronically 
progressive  condition,  sometimes  with  periods  where 
there is a plateau of muscle function, reaching at variable 
age wheelchair dependency.
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